IL326774A - מבני נוגדנים אנטיtslp- ושימושים בהם - Google Patents

מבני נוגדנים אנטיtslp- ושימושים בהם

Info

Publication number
IL326774A
IL326774A IL326774A IL32677426A IL326774A IL 326774 A IL326774 A IL 326774A IL 326774 A IL326774 A IL 326774A IL 32677426 A IL32677426 A IL 32677426A IL 326774 A IL326774 A IL 326774A
Authority
IL
Israel
Prior art keywords
antibody constructs
tslp antibody
tslp
constructs
antibody
Prior art date
Application number
IL326774A
Other languages
English (en)
Original Assignee
Proteologix Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteologix Us Inc filed Critical Proteologix Us Inc
Publication of IL326774A publication Critical patent/IL326774A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL326774A 2023-08-25 2024-08-23 מבני נוגדנים אנטיtslp- ושימושים בהם IL326774A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363578947P 2023-08-25 2023-08-25
PCT/US2024/043747 WO2025049343A1 (en) 2023-08-25 2024-08-23 Anti-tslp antibody constructs and uses thereof

Publications (1)

Publication Number Publication Date
IL326774A true IL326774A (he) 2026-04-01

Family

ID=92931699

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326774A IL326774A (he) 2023-08-25 2024-08-23 מבני נוגדנים אנטיtslp- ושימושים בהם

Country Status (6)

Country Link
AR (1) AR133648A1 (he)
AU (1) AU2024331270A1 (he)
CO (1) CO2026003581A2 (he)
IL (1) IL326774A (he)
TW (1) TW202523697A (he)
WO (1) WO2025049343A1 (he)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
ES2784123T3 (es) * 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
EA038332B1 (ru) * 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
EP4025602A4 (en) * 2019-09-04 2023-12-13 Biosion, Inc. TSLP BINDING ANTIBODIES AND USES THEREOF
TW202140550A (zh) * 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113683694B (zh) * 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用

Also Published As

Publication number Publication date
WO2025049343A1 (en) 2025-03-06
AR133648A1 (es) 2025-10-22
AU2024331270A1 (en) 2026-04-09
CO2026003581A2 (es) 2026-04-06
TW202523697A (zh) 2025-06-16

Similar Documents

Publication Publication Date Title
IL308808A (he) נוגדנים נגד ccr8 ושימושים שלהם
IL319931A (he) נוגדנים אנטי- cd122 ושימושים בהם
GB202017058D0 (en) Antibodies and uses thereof
IL307267A (he) נוגדני anti-cd122 ושימושיהם
IL307439A (he) נוגדים משונים נגד tslp
IL307540A (he) תכשירי נוגדן נגד tslp ושימושים שלהם
IL307940A (he) נוגדנים אנטי- adgre2ושימושים בהם
IL319851A (he) מבני חלבונים קושרים lrrc-15 ושימושים בהם
IL320586A (he) נוגדן נגד trem2 ושימושים שלו
IL317391A (he) נוגדנים חדשים אנטי- lilrb4ושימושים בהם
EP4464722A4 (en) ANTIBODIES AND THEIR USE
IL307939A (he) נוגדנים אנטי- clec12aושימושים בהם
IL319145A (he) נוגדנים חדשים אנטי- lilrb2ושימושים בהם
IL316510A (he) נוגדן אנטי-b7h3 ושימושיו
EP4490199A4 (en) MODIFIED ANTIBODIES AND THEIR USES
EP4437000A4 (en) ANTI-TREM2 ANTIBODY AND ITS USES
IL310028A (he) נוגדן ושימוש בו
IL312584A (he) נוגדני anti-vista ושימושים בהם
IL320972A (he) נוגדנים אנטי-tfr1 ושימושים בהם
IL310810A (he) נוגדנים אנטי- acvr2a ושימושים בהם
IL307233A (he) נוגדנים אנטי- sema3aושימושים בהם
IL326774A (he) מבני נוגדנים אנטיtslp- ושימושים בהם
IL326772A (he) מבני נוגדנים רב-ספציפיים אנטיil-13- ושימושים בהם
GB202303531D0 (en) Antibodies and uses thereof
EP4493597A4 (en) Masp-2-targetting antibodies and uses thereof